risdiplam
Sign in to saveAlso known as RG7916, RO7034067
Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA) and is the first oral medication approved to treat this disease by the US Food and Drug Administration (FDA).
In the Vinony graph
Vinony's link graph records 27 inbound references to risdiplam, and connects out to Hoffmann-La Roche, route of administration and enzyme.
It is catalogued under topics including Drugs developed by Genentech, Drugs developed by Hoffmann-La Roche and Drugs with non-standard legal status.
Vinony links it to 13 Wikipedia language editions.
Key facts
- Drug.image
- Risdiplam.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Evrysdi
- Drug.DailyMedID
- Risdiplam
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- M09
- Drug.ATC_suffix
- AX10
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 1825352-65-5
- Drug.PubChem
- 118513932
- Drug.DrugBank
- DB15305
- Drug.ChemSpiderID
- 67886354
- Drug.UNII
- 76RS4S2ET1
- Drug.KEGG
- D11406
via Wikipedia infobox
Wikidata facts
- Mass
- 401.1964083560002
Show 3 more facts
- canonical SMILES
- CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6
- chemical formula
- C₂₂H₂₃N₇O
- Commons category
- Risdiplam
Sources (2)
via Wikidata · CC0
~5 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Mechanism of action
- Efficacy
- Society and culture
- Legal status
- Names
- Compassionate use
- References
- Further reading
- External links
Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA) and is the first oral medication approved to treat this disease by the US Food and Drug Administration (FDA).
Risdiplam is a survival of motor neuron 2-directed RNA splicing modifier.
Excerpted from Wikipedia’s “risdiplam” article, available under the CC BY-SA 4.0 licence.